Printer Friendly

DOW CORNING RENEWS PLEDGE TO CONTINUED RESEARCH FOLLOWING FDA PANEL RECOMMENDATION

 DOW CORNING RENEWS PLEDGE TO CONTINUED
 RESEARCH FOLLOWING FDA PANEL RECOMMENDATION
 BETHESDA, Md., Feb. 20 /PRNewswire/ -- Following today's vote by an advisory panel of the U.S. Food and Drug Administration, Dow Corning Corporation officials reaffirmed the company's commitment to an ambitious program of safety research in cooperation with the FDA.
 While the company has not made a decision about whether to remain in the breast implant business, it is committed to continued research, said J. Kermit Campbell, Dow Corning Group Vice President.
 "We do not believe that our breast implant products present an unreasonable health risk," Campbell stated. "We were encouraged by the comments of the panel's consultants in rheumatology, who said that evidence does not support a clear link between the devices and scieroderma or other rheumatological diseases. Nonetheless, we are firmly committed to an ambitious program of additional research on the safety of breast implants, which we are undertaking in full cooperation with the FDA."
 The FDA's advisory panel voted 9-0 to recommend limited access to implants for women who need the devices for both reconstruction and augmentation. Augmentation patients, however, would have access only through carefully controlled clinical trials of undetermined size and duration. Patients requiring reconstruction after mastectomy, or those with severe anatomic defects, would have broader access, although still with clearly defined medical protocols.
 The recommendation of the panel, while not binding on the FDA, is typically given great weight. FDA Commissioner David Kessler has committed the agency to issuing its final decision on implant availability within 60 days, or by April 20.
 "While it would be premature to characterize the panel's recommendation in any broad sense, we are hopeful that it will be embodied in a final FDA decision that will allow access to implants for the women who need them," Campbell stated.
 "Our primary commitment is to the women who have our implants," Campbell continued. "We intend to work very hard at generating the additional information that they are telling us they need."
 "We have already committed ourselves to finding effective ways to establish implant tracking, in cooperation with other manufacturers, physicians, patients and the FDA," Campbell said. "This is a step that will have significant benefits both for women, and for our store of knowledge about these devices."
 "In addition, we have a special concern for any woman who has agreed with her physician that for medical reasons her Dow Corning implant should be removed," Campbell said. "We are committed to finding a way of addressing the circumstances of women in such situations who may be uninsured and without the means to pay." For this reason, he said, the company is considering paying up to $1,000 for costs associated with the removal procedure, and will have a further announcement on the subject within two weeks.
 -0- 2/20/92
 /CONTACT: Barie Carmichael of Dow Corning, 301-897-9400, ext. 1602/ CO: Dow Corning Corporation ST: Michigan IN: HEA SU:


KD -- NY109 -- 1209 02/20/92 20:50 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 20, 1992
Words:496
Previous Article:MALAYSIAN GOVERNMENT APPROVES NEW KOMAG MANUFACTURING SUBSIDIARY
Next Article:THE PRESLEY COMPANIES REPORTS FOURTH QUARTER AND YEAR-END RESULTS
Topics:


Related Articles
DOW CORNING STRONGLY DISAGREES WITH FDA PANEL FINDING ON SILICONE BREAST IMPLANTS; PROTESTS INABILITY TO PRESENT ALL OF ITS DATA
DOW CORNING WELCOMES FDA REVIEW OF ADDITIONAL INFORMATION CONCERNING SILICONE BREAST IMPLANTS
DOW CORNING CALLS SID WOLFE CLAIMS '11TH HOUR SHADOWBOXING'
DOW CORNING WRIGHT DISAGREES WITH FDA ANNOUNCEMENT; URGES AGENCY TO MOVE REGULATORY PROCESS AWAY FROM POLITICS, BACK TO SCIENCE
DOW CORNING CALLS UPON KESSLER TO IDENTIFY 'NEW INFORMATION' ECHOES ASPRS RECOMMENDATION OF NEW EXPERT PANEL
DOW CORNING GLAD THAT FDA FINALLY IDENTIFIES WHAT CONSTITUTES NEW INFORMATION CONCERNING BREAST IMPLANTS
DOW CORNING SAYS FDA ALREADY KNEW THEY HAD GO-AHEAD TO RELEASE DOCUMENTS TO PANEL; ALSO KNEW COMPANY TO RELEASE DOCUMENTS TO PUBLIC
ASAPS STATEMENT ON RELEASE OF STUDIES & INTERNAL DOCUMENTS RELATED TO SILICONE-GEL BREAST IMPLANTS BY DOW CORNING
DOW CORNING ANNOUNCES $10 MILLION RESEARCH FUND TO CONTINUE STUDY OF SILICONE BREAST IMPLANT SAFETY
FIRST AND FINAL ADD TO DOW CORNING BREAST IMPLANTS.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters